Alprenolol: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) mNo edit summary |
No edit summary |
||
Line 2: | Line 2: | ||
| verifiedrevid = 443660388 | | verifiedrevid = 443660388 | ||
| IUPAC_name = (''RS'')-1-(2-allylphenoxy)-3-(isopropylamino)propan-2-ol | | IUPAC_name = (''RS'')-1-(2-allylphenoxy)-3-(isopropylamino)propan-2-ol | ||
| image = Alprenolol2. | | image = Alprenolol2.png | ||
<!--Clinical data--> | <!--Clinical data--> | ||
Line 59: | Line 59: | ||
}} | }} | ||
__NOTOC__ | __NOTOC__ | ||
{{CMG}} | {{CMG}}{{AE}}{{SS}} | ||
{{SB}} Atenenol (Tsuruhara Seiyaku, Japan); Elp (Shyh Dar, Taiwan); Skajilol (Kotobuki Seiyaku, Japan) | {{SB}} Atenenol (Tsuruhara Seiyaku, Japan); Elp (Shyh Dar, Taiwan); Skajilol (Kotobuki Seiyaku, Japan) | ||
Line 77: | Line 77: | ||
[[Category:Alcohols]] | [[Category:Alcohols]] | ||
[[Category:Amines]] | [[Category:Amines]] | ||
[[Category:Cardiovascular Drugs]][[Category:Drugs]] |
Revision as of 21:04, 24 July 2014
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
ATC code | |
Pharmacokinetic data | |
Protein binding | 80% - 90% |
Elimination half-life | 2-3 hours → 4-OH-alprenolol |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C15H23NO2 |
Molar mass | 249.34 g/mol |
3D model (JSmol) | |
| |
| |
(verify) |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Synonyms / Brand Names: Atenenol (Tsuruhara Seiyaku, Japan); Elp (Shyh Dar, Taiwan); Skajilol (Kotobuki Seiyaku, Japan)
Overview
Alprenolol, or alfeprol, alpheprol, and alprenololum (Gubernal, Regletin, Yobir, Apllobal, Aptine, Aptol Duriles), is a non-selective beta blocker as well as 5-HT1A receptor antagonist, used in the treatment of angina pectoris.[1] It is no longer marketed by AstraZeneca, but may still be available from other pharmaceutical companies or generically.